Ligand ID: V2H


Drugbank ID:
DB06410
(Doxercalciferol)


Indication:
Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease.

Get human targets for V2H in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'V2H'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		1q2w 3C-LIKE PROTEASE
(SARSr-CoV)		5 / 12
THR A 226
ASN A 228
VAL A 233
ALA A 234
ALA A 266
1.51A20.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		1qz8 POLYPROTEIN 1AB
(SARSr-CoV)		4 / 5
ASN A  33
LEU B  97
GLY A 100
THR A 109
1.31A15.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		1uk4 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 5
ALA A 116
LEU A 141
GLY B 302
THR B 292
1.28A21.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
THR B1226
ASN B1228
ALA B1234
ALA B1266
MET B1235
1.37A21.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.72A21.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		2a5i 3C-LIKE PEPTIDASE
(SARSr-CoV)		5 / 12
THR A 226
ASN A 228
ALA A 234
ALA A 266
MET A 235
1.35A21.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		2a5k 3C-LIKE PEPTIDASE
(SARSr-CoV)		4 / 5
ALA B 116
LEU B 141
GLY A 302
THR A 292
1.30A21.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		2acf REPLICASE
POLYPROTEIN 1AB
(SARS-COV
Tor2)		4 / 5
ASN B 219
ALA B 311
LEU B 291
GLY B 279
1.31A17.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		2ajf ACE2
(Homo
sapiens)		5 / 12
MET B 474
ALA B 501
GLU B 181
MET B 123
THR B 122
1.54A21.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		2alv REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.76A20.74
None
CY6  A1145 (-4.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		2amd 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
THR B 226
ASN B 228
VAL B 233
ALA B 234
ALA B 266
1.56A21.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		2amd 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 5
ALA A 116
LEU A 141
GLY B 302
THR B 292
1.18A21.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		2d2d 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.64A21.31
None
ENB  A 307 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		2dd8 IGG LIGHT CHAIN
(Homo
sapiens)		5 / 12
VAL L 208
ALA L 209
ALA L 151
GLU L 205
THR L 117
1.58A16.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		2fav REPLICASE
POLYPROTEIN 1AB
(PP1AB) (ORF1AB)
(SARSr-CoV)		4 / 5
ASN A  38
ALA A 130
LEU A 110
GLY A  98
1.23A17.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		2gdt LEADER PROTEIN
P65 HOMOLOG
NSP1
(SARSr-CoV)		3 / 3
VAL A  95
LEU A  45
GLY A  87
0.58A15.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		2gtb 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.78A21.56
None
AZP  A 401 ( 4.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		2gx4 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.74A21.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		2h85 PUTATIVE ORF1AB
POLYPROTEIN
(SARSr-CoV)		3 / 3
VAL A 162
LEU A 167
GLY A 169
0.72A20.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		2op9 REPLICASE
POLYPROTEIN 1AB
(PP1AB, ORF1AB)
3C-LIKE PROTEINASE
(3CL-PRO, 3CLP)
(SARSr-CoV)		3 / 3
VAL B  20
LEU B  27
GLY B 146
0.78A21.21
None
WR1  B 602 ( 4.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		3 / 3
VAL C 162
LEU C 167
GLY C 169
0.65A20.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		2q6g REPLICASE
POLYPROTEIN 1AB
(SARS-COV
BJ01)		4 / 5
ALA A 116
LEU A 141
GLY B 302
THR B 292
1.22A20.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		2qc2 3C-LIKE PROTEINASE
(-)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.75A21.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		2qcy 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
THR A 226
ASN A 228
VAL A 233
ALA A 234
ALA A 266
1.53A21.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		2qiq REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
THR A 226
ASN A 228
VAL A 233
ALA A 234
ALA A 266
1.57A21.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		2qiq REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.76A21.21
None
CYV  A 302 ( 4.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
VAL C  24
VAL C   9
GLU C  41
VAL F  51
ILE C  27
1.29A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		3 / 3
VAL D 162
LEU D 167
GLY D 169
0.57A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 5
ASN D  29
ALA B  30
LEU B   2
THR D 105
1.35A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		2wct NSP3
(SARSr-CoV)		5 / 12
MET A 444
PHE B 406
ALA D 555
GLU B 402
ILE B 394
1.48A20.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		4 / 5
ASN A 198
ALA A 168
LEU A  85
GLY A  81
1.40A19.09
None
None
None
SAH  A1293 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		2xyr PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		4 / 5
ASN A 198
ALA A 168
LEU A  85
GLY A  81
1.37A19.21
None
None
None
SFG  A1298 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		3aw0 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.69A21.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		3aw0 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
THR A 226
ASN A 228
ALA A 234
ALA A 266
MET A 235
1.36A21.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		3d62 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.79A20.95
None
959  A 350 ( 4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		3ea8 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.73A21.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		3eaj 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
VAL B  20
LEU B  27
GLY B 146
0.76A21.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		3eaj 3C-LIKE PROTEINASE
(SARSr-CoV)		6 / 12
THR A 226
ASN A 228
VAL A 233
ALA A 234
ALA A 266
MET A 235
1.66A21.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		3f9h 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
VAL B  20
LEU B  27
GLY B 146
0.77A21.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		3m3s 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.78A21.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		3m3t 3C-LIKE PROTEINASE
(SARSr-CoV)		6 / 12
THR A 226
ASN A 228
VAL A 233
ALA A 234
ALA A 266
MET A 235
1.58A21.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		3m3v 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.77A21.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		3mj5 REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		4 / 5
ASN A 157
LEU A  59
GLY A  82
THR B 198
1.17A21.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		4 / 5
ASN A 198
ALA A 168
LEU A  85
GLY A  81
1.41A20.12
None
None
None
SAM  A 302 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
THR B 347
PHE B 504
THR B 125
ILE B  54
THR B 129
1.52A21.57
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		3sna 3C-LIKE PROTEINASE
(SARSr-CoV)		6 / 12
THR A 226
ASN A 228
VAL A 233
ALA A 234
ALA A 266
MET A 235
1.59A20.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		4hi3 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.77A22.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		4hi3 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
THR A 226
ASN A 228
ALA A 234
ALA A 266
MET A 235
1.53A22.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		4mds 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.76A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		5b6o 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
THR A 226
ASN A 228
ALA A 234
ALA A 266
MET A 235
1.55A21.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		5b6o 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.79A21.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		5r7z 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.71A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
VAL A  42
LEU A  27
GLY A 146
1.50A17.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.75A17.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
VAL A 148
LEU A  30
GLY A  29
1.63A17.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 5
ASN A 119
ALA A 116
LEU A  30
GLY A  29
1.61A17.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
VAL A 247
LEU A 250
GLY A 251
1.49A17.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
VAL A 261
LEU A 250
GLY A 251
1.67A17.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
MET A  17
PHE A 150
VAL A 157
VAL A 114
GLU A  14
1.79A17.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
PHE A 305
ALA A 609
VAL A 581
TYR A 598
VAL A 537
1.36A15.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		5x59 S PROTEIN
(MERS-CoV)		4 / 5
ALA B 962
LEU A 780
GLY A1170
THR A1187
1.33A16.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		6 / 12
PHE B1071
ALA C 881
ALA B1062
GLU C 900
ILE C 905
MET C 884
1.69A15.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
PHE B 305
VAL B 307
ALA B 609
VAL B 581
VAL B 537
1.32A16.54
PHE  B 305 ( 1.3A)
VAL  B 307 ( 0.6A)
ALA  B 609 ( 0.0A)
VAL  B 581 ( 0.6A)
VAL  B 537 ( 0.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ASN C1090
VAL C1050
ALA B 872
ILE C 891
THR C1048
1.48A16.54
ASN  C1090 ( 0.6A)
VAL  C1050 ( 0.6A)
ALA  B 872 ( 0.0A)
ILE  C 891 ( 0.7A)
THR  C1048 ( 0.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 5
ASN A 838
ALA A 834
LEU B 571
THR A  51
1.33A16.54
ASN  A 838 ( 0.6A)
ALA  A 834 ( 0.0A)
LEU  B 571 ( 0.6A)
THR  A  51 ( 0.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ALA A 881
ALA B1062
GLU A 900
ILE A 905
MET A 884
1.43A15.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 5
ASN A 733
ALA A 971
LEU A 978
THR B 535
1.24A15.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR C 631
VAL C 581
VAL C 606
ILE C 299
THR C 302
1.16A15.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
THR B 631
VAL B 581
VAL B 606
ILE B 299
THR B 302
1.15A15.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 5
ASN C 733
ALA C 971
LEU C 978
THR B 535
1.27A15.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 5
ASN C  29
ALA C 249
LEU C 235
GLY C  77
1.08A15.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
THR B 631
VAL B 581
VAL B 606
ILE B 299
THR B 302
0.96A15.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		3 / 3
VAL A  98
LEU A 235
GLY A  77
0.60A15.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ASN A1090
VAL A1050
ALA B 872
ILE A 891
THR A1048
1.49A15.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6jyt HELICASE
(SARSr-CoV)		4 / 5
ALA B 292
LEU B 280
GLY B 400
THR B 566
1.41A21.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6jyt HELICASE
(SARSr-CoV)		5 / 12
THR A 547
VAL A 510
ALA A 509
ALA A 522
ILE A 572
1.50A21.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6lze VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
VAL A 247
LEU A 250
GLY A 251
1.50A19.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6lze VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.76A19.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 5
ASN A 119
ALA A 116
LEU A  30
GLY A  29
1.62A19.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
THR A  98
VAL A  18
ALA A  70
VAL A 148
VAL A  77
1.76A19.55
None
DMS  A 403 ( 4.9A)
DMS  A 403 ( 3.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
THR A 175
VAL A  36
VAL A 148
TYR A 161
VAL A  77
1.75A19.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6lze VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
VAL A  42
LEU A  27
GLY A 146
1.55A19.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.77A20.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
VAL A 247
LEU A 250
GLY A 251
1.49A20.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
VAL A  42
LEU A  27
GLY A 146
1.54A20.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 5
ASN A 119
ALA A 116
LEU A  30
GLY A  29
1.63A20.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6m18 ACE2
(Homo
sapiens)		5 / 12
PHE D 643
VAL D 647
ALA D 650
ALA D 714
ILE D 727
1.57A19.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
MET A  17
PHE A 150
VAL A 157
VAL A 114
GLU A  14
1.78A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
VAL D 261
LEU D 250
GLY D 251
1.57A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
VAL C 247
LEU C 250
GLY C 251
1.47A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
VAL C  42
LEU C  27
GLY C 146
1.54A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
ALA B 116
LEU B 141
GLY D 302
THR D 292
1.42A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
THR D 257
VAL D 204
ALA D 206
ALA D 211
THR D 201
1.80A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
THR D 226
VAL D 233
ALA D 234
ALA D 266
MET D 235
1.77A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
VAL C  20
LEU C  27
GLY C 146
0.76A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
THR C  98
VAL C  18
ALA C  70
VAL C 148
VAL C  77
1.76A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
THR A 175
VAL A  36
VAL A 148
TYR A 161
VAL A  77
1.68A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
ASN D 119
ALA D 116
LEU D  30
GLY D  29
1.60A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
ALA A 116
LEU A 141
GLY C 302
THR C 292
1.39A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
VAL B 247
LEU B 250
GLY B 251
1.48A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
VAL A 247
LEU A 250
GLY A 251
1.49A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
VAL D  42
LEU D  27
GLY D 146
1.53A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
VAL B  20
LEU B  27
GLY B 146
0.81A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
THR B  98
VAL B  18
ALA B  70
VAL B 148
VAL B  77
1.78A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
ASN A 228
VAL A 233
ALA A 234
ALA A 266
MET A 235
1.75A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
THR A  98
VAL A  18
ALA A  70
VAL A 148
VAL A  77
1.75A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
ASN B 119
ALA B 116
LEU B  30
GLY B  29
1.64A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
VAL D  20
LEU D  27
GLY D 146
0.72A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
VAL D 247
LEU D 250
GLY D 251
1.47A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
THR B 175
VAL B  36
VAL B 148
TYR B 161
VAL B  77
1.72A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
MET B  17
PHE B 150
VAL B 157
VAL B 114
GLU B  14
1.77A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.79A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 5
ASN C 119
ALA C 116
LEU C  30
GLY C  29
1.63A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 12
MET A  17
PHE A 150
VAL A 157
VAL A 114
GLU A  14
1.80A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 5
ASN A 119
ALA A 116
LEU A  30
GLY A  29
1.62A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6m2q 3CL PROTEASE
(SARS-CoV-2)		3 / 3
VAL A  42
LEU A  27
GLY A 146
1.52A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6m2q 3CL PROTEASE
(SARS-CoV-2)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.76A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 12
ASN A 228
VAL A 233
ALA A 234
ALA A 266
MET A 235
1.59A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6m2q 3CL PROTEASE
(SARS-CoV-2)		3 / 3
VAL A 247
LEU A 250
GLY A 251
1.49A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6m71 NSP12
(SARS-CoV-2)		5 / 12
MET A 755
VAL A 693
ALA A 699
THR A 686
ILE A 579
1.60A20.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6m71 NSP12
(SARS-CoV-2)		3 / 3
VAL A 763
LEU A 614
GLY A 808
1.17A20.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6m71 NSP12
(SARS-CoV-2)		5 / 12
THR A 567
VAL A 535
ALA A 660
VAL A 373
VAL A 299
1.50A20.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6m71 NSP12
(SARS-CoV-2)		4 / 5
ASN A 790
ALA A 634
LEU A 663
GLY A 679
1.56A20.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6m71 NSP12
(SARS-CoV-2)		5 / 12
MET A 615
ALA A 777
VAL A 472
ILE A 696
THR A 701
1.67A20.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6m71 NSP12
(SARS-CoV-2)		5 / 12
PHE A 745
ALA A 777
VAL A 475
TYR A 746
THR A 710
1.76A20.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6m71 NSP12
(SARS-CoV-2)		5 / 12
PHE A 753
VAL A 776
VAL A 587
MET A 756
THR A 586
1.52A20.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6m71 NSP12
(SARS-CoV-2)		5 / 12
VAL A 693
ALA A 690
ALA A 639
THR A 586
ILE A 589
1.70A20.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6m71 NSP12
NSP8
(SARS-CoV-2)		4 / 5
ASN B 100
ALA A 379
LEU A 401
GLY A 385
1.56A17.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6m71 NSP12
NSP8
(SARS-CoV-2)		5 / 12
MET B  87
THR B  84
ALA A 375
MET A 566
THR A 567
1.80A17.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6m71 NSP12
NSP8
(SARS-CoV-2)		5 / 12
VAL B 130
ALA B 188
ALA A 400
THR B 137
THR B 141
1.68A17.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6m71 NSP12
NSP8
(SARS-CoV-2)		4 / 5
ASN A 507
ALA B  86
LEU B  91
THR A 402
1.45A20.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6m71 NSP12
(SARS-CoV-2)		4 / 5
ASN A 507
ALA A 558
LEU A 544
THR A 402
1.63A20.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6m71 NSP8
(SARS-CoV-2)		5 / 12
VAL B 130
ALA B 188
THR B 137
ILE B 172
THR B 141
1.58A17.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6m71 NSP12
(SARS-CoV-2)		4 / 5
ALA A 690
LEU A 663
GLY A 679
THR A 556
1.42A20.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6m71 NSP12
(SARS-CoV-2)		5 / 12
PHE A 317
VAL A 315
ALA A 311
ILE A 466
MET A 629
1.71A20.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 5
ASN A 528
ALA A 508
GLY A 512
THR A 372
1.40A15.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR C 631
VAL C 581
VAL C 606
ILE C 299
THR C 302
0.95A15.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
HEAVY CHAIN
(Homo
sapiens)		4 / 5
ALA H  23
LEU H  20
GLY H   8
THR H 165
1.24A19.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6nur NSP12
(SARSr-CoV)		4 / 5
ASN A 705
ALA A 125
LEU A 142
THR A 462
1.18A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6nur NSP12
NSP8
(SARSr-CoV)		4 / 5
ASN B 100
ALA A 379
LEU A 401
GLY A 385
1.37A16.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6nur NSP12
(SARSr-CoV)		5 / 12
PHE A 753
VAL A 776
VAL A 587
MET A 756
THR A 586
1.46A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6nur NSP12
(SARSr-CoV)		5 / 12
MET A 755
VAL A 693
ALA A 699
THR A 687
ILE A 589
1.43A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
THR A 645
VAL A 595
THR A 299
ILE A 312
THR A 315
1.32A17.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		6 / 12
PHE A 400
VAL A 512
ALA A 397
VAL A 350
TYR A 451
THR A 430
1.75A17.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
VAL A 951
LEU A 948
GLY A1059
0.68A17.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 5
ASN B 542
ALA B 522
GLY B 526
THR B 385
1.39A17.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6vxs NSP3
(SARS-CoV-2)		4 / 5
ASN A  37
ALA A 129
LEU A 109
GLY A  97
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6vxs NSP3
(SARS-CoV-2)		3 / 3
VAL B  41
LEU B  75
GLY B  79
1.33A
None
SO4  B 201 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6vxs NSP3
(SARS-CoV-2)		5 / 12
VAL A  34
ALA A  89
VAL A 151
TYR A  17
GLU A 120
1.42A
NHE  A 202 (-4.9A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6vxs NSP3
(SARS-CoV-2)		3 / 3
VAL A  41
LEU A  75
GLY A  79
1.35A
None
SO4  A 201 (-4.1A)
SO4  A 201 ( 4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6vxs NSP3
(SARS-CoV-2)		5 / 12
VAL B  34
ALA B  89
VAL B 151
TYR B  17
GLU B 120
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
THR C 645
VAL C 595
VAL C 620
ILE C 312
THR C 315
1.29A17.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
THR C 645
VAL C 595
THR C 299
ILE C 312
THR C 315
1.44A17.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 5
ASN A 542
ALA A 522
GLY A 526
THR A 385
1.40A17.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
THR A 645
VAL A 595
THR A 299
ILE A 312
THR A 315
1.43A17.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
THR C 645
VAL C 595
VAL C 620
ILE C 312
THR C 315
1.30A17.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		4 / 5
ASN L  22
ALA L  51
LEU L  27
GLY L  68
1.26A15.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 5
ALA H  78
LEU H   4
GLY H 104
THR H   9
1.69A16.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		4 / 5
ASN L 137
ALA L 111
LEU L 201
THR H 131
1.36A15.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		5 / 12
PHE H  29
ALA H  93
ILE H  50
MET H 100
THR H 100
1.52A16.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		4 / 5
ALA H 168
LEU H 170
GLY H 174
THR L 129
1.69A16.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		3 / 3
VAL H 111
LEU H  82
GLY H  15
1.57A16.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		3 / 3
VAL L  13
LEU L  78
GLY L  16
1.62A15.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		3 / 3
VAL L 133
LEU H 124
GLY H 139
1.74A15.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		3 / 3
VAL L  27
LEU L  27
GLY L  68
1.01A15.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		3 / 3
VAL H  37
LEU H  45
GLY H  44
1.58A16.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		5 / 12
VAL L 104
ALA L  12
ALA L  80
GLU L 165
THR L 102
1.79A15.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		5 / 12
PHE H  29
ALA H  93
ILE H  50
MET H 100
THR H 100
1.52A16.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		3 / 3
VAL H 102
LEU H   4
GLY H 104
1.63A16.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		3 / 3
VAL H 102
LEU H   4
GLY H  24
1.28A16.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w4b NSP9
(SARS-CoV-2)		4 / 5
ASN A  34
LEU B  98
GLY A 101
THR A 110
1.14A15.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w4h NSP16
(SARS-CoV-2)		4 / 5
ASN A6996
ALA A6966
LEU A6883
GLY A6879
1.38A18.12
ACT  A7103 (-3.3A)
None
None
SAM  A7102 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
VAL A6882
ALA A6881
ALA A6870
ILE A6838
MET B4297
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASN A7083
ALA A6858
LEU A6961
THR A6918
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASN A6996
ALA A6966
LEU A6883
GLY A6879
1.43A
None
None
None
SAM  A7104 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
VAL A6965
LEU A6959
GLY A6963
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASN A6853
ALA A6843
GLY A6806
THR A6989
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
THR A6993
ASN A6996
ALA A6990
GLU A7001
THR A6934
1.64A
None
None
None
None
KCX  A6935 ( 3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
THR A  98
VAL A  18
ALA A  70
VAL A 148
VAL A  77
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.81A
None
X77  A 401 ( 3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
THR A 175
VAL A  36
VAL A 148
TYR A 161
VAL A  77
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 5
ASN A 119
ALA A 116
LEU A  30
GLY A  29
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
VAL A 247
LEU A 250
GLY A 251
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w6y NSP3
(SARS-CoV-2)		3 / 3
VAL A 165
LEU A  12
GLY B   8
1.15A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w6y NSP3
(SARS-CoV-2)		3 / 3
VAL A 165
LEU A 169
GLY B   8
0.84A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w6y NSP3
(SARS-CoV-2)		4 / 5
ASN A  37
ALA A 129
LEU A 109
GLY A  97
1.41A
None
AMP  A 201 ( 3.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w6y NSP3
(SARS-CoV-2)		3 / 3
VAL B 165
LEU B  10
GLY A   8
1.06A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6w6y NSP3
(SARS-CoV-2)		5 / 12
VAL B  34
ALA B  89
VAL B 151
TYR B  17
GLU B 120
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w6y NSP3
(SARS-CoV-2)		3 / 3
VAL B  95
LEU B 127
GLY B  97
1.76A16.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w6y NSP3
(SARS-CoV-2)		3 / 3
VAL A  95
LEU A 127
GLY A  97
1.75A16.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w6y NSP3
(SARS-CoV-2)		4 / 5
ASN B  37
ALA B 129
LEU B 109
GLY B  97
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w6y NSP3
(SARS-CoV-2)		3 / 3
VAL A 165
LEU A  10
GLY B   8
1.18A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w6y NSP3
(SARS-CoV-2)		3 / 3
VAL B  41
LEU B  75
GLY B  79
1.25A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w6y NSP3
(SARS-CoV-2)		3 / 3
VAL B 165
LEU B 169
GLY A   8
0.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w6y NSP3
(SARS-CoV-2)		3 / 3
VAL A  41
LEU A  75
GLY A  79
1.26A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w75 NSP16
(SARS-CoV-2)		4 / 5
ASN A6996
ALA A6966
LEU A6883
GLY A6879
1.39A15.03
FMT  A7104 ( 3.3A)
None
None
SAM  A7102 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w75 NSP16
(SARS-CoV-2)		4 / 5
ASN A6841
ALA A6966
GLY A6869
THR A6934
1.65A15.03
SAM  A7102 ( 3.4A)
None
SAM  A7102 ( 3.8A)
FMT  A7103 ( 4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w75 NSP16
(SARS-CoV-2)		4 / 5
ASN A6853
ALA A6843
GLY A6806
THR A6989
1.65A15.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w75 NSP16
(SARS-CoV-2)		4 / 5
ASN C7083
ALA C6858
LEU C6961
THR C6918
1.51A15.03
None
None
None
FMT  C7113 ( 4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w75 NSP16
(SARS-CoV-2)		3 / 3
VAL C6965
LEU C6959
GLY C6963
1.48A15.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w75 NSP16
(SARS-CoV-2)		4 / 5
ASN C6853
ALA C6843
GLY C6806
THR C6989
1.67A15.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6w75 NSP10
NSP16
(SARS-CoV-2)		5 / 12
VAL A6882
ALA A6881
ALA A6870
ILE A6838
MET B4297
1.64A15.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6w75 NSP16
(SARS-CoV-2)		5 / 12
THR A6993
ASN A6996
ALA A6990
GLU A7001
THR A6934
1.61A15.03
None
FMT  A7104 ( 3.3A)
None
FMT  A7104 ( 4.0A)
FMT  A7103 ( 4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w75 NSP16
(SARS-CoV-2)		4 / 5
ASN C6996
ALA C6966
LEU C6883
GLY C6879
1.39A15.03
FMT  C7108 ( 3.4A)
None
None
SAM  C7105 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6w75 NSP10
NSP16
(SARS-CoV-2)		5 / 12
VAL C6882
ALA C6881
ALA C6870
ILE C6838
MET D4297
1.66A15.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w75 NSP16
(SARS-CoV-2)		4 / 5
ASN A7083
ALA A6858
LEU A6961
THR A6918
1.52A15.03
None
None
None
FMT  A7109 ( 4.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6w75 NSP16
(SARS-CoV-2)		3 / 3
VAL A6965
LEU A6959
GLY A6963
1.47A15.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
THR A 119
ALA A 139
VAL A  98
ILE A 151
THR A  90
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 5
ALA B 107
LEU A 162
GLY A 271
THR B 265
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
THR A  10
ASN A  13
ALA A 131
ALA A  68
THR A  90
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
VAL B  21
VAL B  57
TYR B  56
MET B  23
THR B   4
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 5
ASN C 156
ALA C 149
GLY C  81
THR C  75
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
THR C 119
ALA C 139
VAL C  98
ILE C 151
THR C  90
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
THR B  10
ASN B  13
ALA B 131
ALA B  68
THR B  90
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 5
ALA C 153
LEU C  87
GLY C  38
THR C   9
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 5
ASN C 156
LEU C  80
GLY C  81
THR A  42
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 5
ASN B 110
ALA B 145
LEU B 150
THR B 119
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 5
ALA B 153
LEU B  87
GLY B  38
THR B   9
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
VAL C  21
VAL C  57
TYR C  56
MET C  23
THR C   4
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 5
ASN C 156
ALA A 107
LEU C 162
GLY C 163
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
VAL A  21
VAL A  57
TYR A  56
MET A  23
THR A   4
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 5
ALA B 107
LEU A 162
GLY A 163
THR A 301
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 5
ASN A 110
ALA A 145
LEU A 150
THR A 119
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 5
ALA A 153
LEU A  87
GLY A  38
THR A   9
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 5
ASN C 110
ALA C 145
LEU C 150
THR C 119
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6wcf NSP3
(SARS-CoV-2)		3 / 3
VAL A  41
LEU A  75
GLY A  79
1.26A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wcf NSP3
(SARS-CoV-2)		4 / 5
ASN A  37
ALA A 129
LEU A 109
GLY A  97
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6wen NSP3
(SARS-CoV-2)		3 / 3
VAL A  41
LEU A  75
GLY A  79
1.30A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wen NSP3
(SARS-CoV-2)		4 / 5
ASN A  37
ALA A 129
LEU A 109
GLY A  97
1.30A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6wen NSP3
(SARS-CoV-2)		5 / 12
MET A  61
THR A  57
VAL A  36
VAL A  49
VAL A 121
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6wen NSP3
(SARS-CoV-2)		5 / 12
VAL A  35
ALA A  89
VAL A  49
GLU A  26
VAL A 121
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6wen NSP3
(SARS-CoV-2)		5 / 12
VAL A  34
ALA A  89
VAL A 151
TYR A  17
GLU A 120
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6wey NSP3
(SARS-CoV-2)		5 / 12
VAL A 238
ALA A 293
VAL A 355
TYR A 221
GLU A 324
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6wey NSP3
(SARS-CoV-2)		3 / 3
VAL A 245
LEU A 279
GLY A 283
1.24A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wey NSP3
(SARS-CoV-2)		4 / 5
ASN A 241
ALA A 333
LEU A 313
GLY A 301
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6wiq NSP7
NSP8
(SARS-CoV-2)		5 / 12
THR A   9
PHE A  49
VAL A  53
ALA A  48
ILE B 107
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 5
ASN B 354
LEU B 291
GLY B 287
THR A 332
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 5
ASN E 354
LEU E 291
GLY E 287
THR F 332
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 5
ASN D 354
LEU D 291
GLY D 287
THR C 332
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
THR A6993
ASN A6996
ALA A6990
GLU A7001
THR A6934
1.62A
None
None
None
None
FMT  A7103 (-4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASN C6841
ALA C6966
GLY C6869
THR C6934
1.62A
SAH  C7102 (-3.7A)
None
SAH  C7102 (-3.8A)
FMT  C7104 (-4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASN A7083
ALA A6858
LEU A6961
THR A6918
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASN C6996
ALA C6966
LEU C6883
GLY C6879
1.39A
None
None
None
SAH  C7102 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASN A6853
ALA A6843
GLY A6806
THR A6989
1.63A
FMT  A7107 (-3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
THR C6993
ASN C6996
ALA C6990
GLU C7001
THR C6934
1.60A
None
None
None
None
FMT  C7104 (-4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
VAL A6965
LEU A6959
GLY A6963
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASN C6853
ALA C6843
GLY C6806
THR C6989
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
VAL C6882
ALA C6881
ALA C6870
ILE C6838
MET D4297
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASN A6996
ALA A6966
LEU A6883
GLY A6879
1.39A
None
None
None
SAH  A7102 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
VAL A6882
ALA A6881
ALA A6870
ILE A6838
MET B4297
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
VAL C6965
LEU C6959
GLY C6963
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASN A6841
ALA A6966
GLY A6869
THR A6934
1.68A
SAH  A7102 (-3.6A)
None
SAH  A7102 (-3.8A)
FMT  A7103 (-4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASN C7083
ALA C6858
LEU C6961
THR C6918
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6wkq NSP16
(SARS-CoV-2)		3 / 3
VAL A6965
LEU A6959
GLY A6963
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6wkq NSP16
(SARS-CoV-2)		5 / 12
THR C6993
ASN C6996
ALA C6990
GLU C7001
THR C6934
1.61A
None
None
None
None
FMT  C7104 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wkq NSP16
(SARS-CoV-2)		4 / 5
ASN C6996
ALA C6966
LEU C6883
GLY C6879
1.38A
None
None
None
SFG  C7103 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wkq NSP16
(SARS-CoV-2)		4 / 5
ASN A7083
ALA A6858
LEU A6961
THR A6918
1.50A
None
None
None
FMT  A7108 ( 4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6wkq NSP16
(SARS-CoV-2)		5 / 12
THR A6993
ASN A6996
ALA A6990
GLU A7001
THR A6934
1.62A
None
None
None
None
FMT  A7105 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wkq NSP16
(SARS-CoV-2)		4 / 5
ASN A6853
ALA A6843
GLY A6806
THR A6989
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wkq NSP16
(SARS-CoV-2)		4 / 5
ASN A6996
ALA A6966
LEU A6883
GLY A6879
1.39A
None
None
None
SFG  A7103 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6wkq NSP10
NSP16
(SARS-CoV-2)		5 / 12
VAL A6882
ALA A6881
ALA A6870
ILE A6838
MET B4297
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wkq NSP16
(SARS-CoV-2)		4 / 5
ASN C6853
ALA C6843
GLY C6806
THR C6989
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6wkq NSP10
NSP16
(SARS-CoV-2)		5 / 12
VAL C6882
ALA C6881
ALA C6870
ILE C6838
MET D4297
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wkq NSP16
(SARS-CoV-2)		4 / 5
ASN A6841
ALA A6966
GLY A6869
THR A6934
1.66A
FMT  A7104 ( 3.1A)
None
SFG  A7103 ( 3.8A)
FMT  A7105 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6wkq NSP16
(SARS-CoV-2)		3 / 3
VAL C6965
LEU C6959
GLY C6963
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 5
ASN B  74
ALA B  81
LEU B 120
THR B  49
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 5
ASN A  74
ALA A  81
LEU A 120
THR A  49
1.63A
EDO  A 406 (-4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
VAL B  54
VAL B  32
TYR B  33
MET B 105
THR B 106
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
THR B  31
VAL B  10
ALA B  60
VAL B  25
GLU B  42
1.63A
None
None
None
None
EDO  B 411 (-4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
THR A  98
VAL A  18
ALA A  70
VAL A 148
VAL A  77
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 5
ASN A 119
ALA A 116
LEU A  30
GLY A  29
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.77A
None
U5G  A 401 ( 4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
VAL A 247
LEU A 250
GLY A 251
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
VAL A  42
LEU A  27
GLY A 146
1.54A
None
U5G  A 401 ( 4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
MET A  17
PHE A 150
VAL A 157
VAL A 114
GLU A  14
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
ASN D  37
ALA D 129
LEU D 109
GLY D  97
1.40A
None
APR  D 201 (-3.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
ASN A  37
ALA A 129
LEU A 109
GLY A  97
1.40A
None
APR  A 201 (-3.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL B  34
ALA B  89
VAL B 151
TYR B  17
GLU B 120
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
VAL A  41
LEU A  75
GLY A  79
1.30A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL B 151
ALA B 124
ALA B 112
THR B  13
ILE B  18
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL A  34
ALA A  89
VAL A 151
TYR A  17
GLU A 120
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
VAL D  41
LEU D  75
GLY D  79
1.27A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
VAL B  41
LEU B  75
GLY B  79
1.31A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL D 151
ALA D 124
ALA D 112
THR D  13
ILE D  18
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
VAL C  41
LEU C  75
GLY C  79
1.26A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL C  34
ALA C  89
VAL C 151
TYR C  17
GLU C 120
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL A 151
ALA A 124
ALA A 112
THR A  13
ILE A  18
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL D  34
ALA D  89
VAL D 151
TYR D  17
GLU D 120
1.63A
None
None
None
None
APR  A 201 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASN A6996
ALA A6966
LEU A6883
GLY A6879
1.43A
GTA  A7102 (-3.9A)
None
None
SAH  A7101 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
THR A6993
ASN A6996
ALA A6990
GLU A7001
THR A6934
1.58A
None
GTA  A7102 (-3.9A)
None
GTA  A7102 (-4.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASN A6853
ALA A6843
GLY A6806
THR A6989
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASN A7083
ALA A6858
LEU A6961
THR A6918
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASN A6841
ALA A6966
GLY A6869
THR A6934
1.73A
SO4  A7109 ( 3.2A)
None
SAH  A7101 (-3.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
VAL A6995
ALA A6832
VAL A6842
ILE A6838
MET A6840
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
VAL A6995
ALA A6832
ALA A6802
ILE A6838
MET A6840
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6wq3 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
VAL A6882
ALA A6881
ALA A6870
ILE A6838
MET B4297
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
VAL A6995
ALA A6832
THR A6846
ILE A6838
MET A6840
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
VAL A6965
LEU A6959
GLY A6963
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 12
THR A   9
PHE A  49
VAL A  53
ALA A  48
ILE B 107
1.70A
None
None
EDO  B 302 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 12
THR C   9
PHE C  49
VAL C  53
ALA C  48
ILE D 107
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wqd NSP7
NSP8
(SARS-CoV-2)		4 / 5
ASN A  69
ALA B 110
GLY A  64
THR B  84
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
VAL A 247
LEU A 250
GLY A 251
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
THR A 175
VAL A  36
VAL A 148
TYR A 161
VAL A  77
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ASN A 228
VAL A 233
ALA A 234
ALA A 266
MET A 235
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
THR A  98
VAL A  18
ALA A  70
VAL A 148
VAL A  77
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
VAL A  42
LEU A  27
GLY A 146
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 12
THR A  10
ASN A  13
ALA A 131
ALA A  68
THR A  90
1.70A
 CL  A 506 (-4.0A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 12
THR A  18
PHE A  31
VAL A  57
VAL A   2
MET A  23
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 5
ALA A 153
LEU A  87
GLY A  38
THR A   9
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 12
VAL A  21
VAL A  57
TYR A  56
MET A  23
THR A   4
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 5
ASN A 110
ALA A 145
LEU A 150
THR A 119
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 5
ASN A 308
ALA A 204
LEU A 178
THR A 259
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6y2g REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
THR A 226
ASN A 228
ALA A 234
ALA A 266
MET A 235
1.53A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
VAL A 247
LEU A 250
GLY A 251
1.49A17.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
VAL A 148
LEU A  30
GLY A  29
1.64A17.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
ASN A 119
ALA A 116
LEU A  30
GLY A  29
1.60A17.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
VAL A 261
LEU A 250
GLY A 251
1.69A17.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
VAL A  42
LEU A  27
GLY A 146
1.50A17.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.74A17.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 5
ASN C  69
ALA D 110
GLY C  64
THR D  84
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 12
THR A   9
PHE A  49
VAL A  53
ALA A  48
ILE B 107
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 5
ASN A  69
ALA B 110
GLY A  64
THR B  84
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 12
THR C   9
PHE C  49
VAL C  53
ALA C  48
ILE D 107
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 12
PHE B  29
ALA B  97
ILE B  50
MET B 106
THR B 104
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6yla HEAVY CHAIN
(Homo
sapiens)		3 / 3
VAL H 108
LEU H   4
GLY H  24
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 5
ALA H 172
LEU H 174
GLY H 178
THR L 135
1.67A
None
MLI  H 304 (-4.8A)
MLI  H 301 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 12
THR H 155
TYR H 149
VAL B 115
ILE B  20
THR B 116
1.69A
MLI  H 305 ( 4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 5
ALA B 172
LEU B 174
GLY B 178
THR C 135
1.70A
None
None
MLI  B 301 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6yla HEAVY CHAIN
(Homo
sapiens)		3 / 3
VAL B 108
LEU B   4
GLY B  24
1.27A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 12
PHE H  29
ALA H  97
ILE H  50
MET H 106
THR H 104
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 12
PHE B  29
ALA B  97
ILE B  50
MET B 106
THR B 104
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 12
PHE H  29
ALA H  97
ILE H  50
MET H 106
THR H 104
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 5
ALA A 372
LEU L  15
GLY L  16
THR L  80
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ym0 HEAVY CHAIN
(Homo
sapiens)		3 / 3
VAL H 108
LEU H   4
GLY H  24
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
VAL E 350
ALA E 348
VAL E 512
TYR E 396
ILE E 468
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6ym0 HEAVY CHAIN
(Homo
sapiens)		5 / 12
PHE H  29
ALA H  97
ILE H  50
MET H 106
THR H 104
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6ym0 HEAVY CHAIN
(Homo
sapiens)		5 / 12
PHE H  29
ALA H  97
ILE H  50
MET H 106
THR H 104
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 5
ALA H 172
LEU H 174
GLY H 178
THR L 135
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
VAL A  42
LEU A  27
GLY A 146
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
VAL A 247
LEU A 250
GLY A 251
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 5
ALA E 475
LEU E 455
GLY B  15
THR B 116
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6yor IGG H CHAIN
(Homo
sapiens)		3 / 3
VAL H 108
LEU H   4
GLY H  24
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6yor IGG H CHAIN
(Homo
sapiens)		5 / 12
PHE B  29
ALA B  97
ILE B  50
MET B 106
THR B 104
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6yor IGG H CHAIN
(Homo
sapiens)		5 / 12
PHE H  29
ALA H  97
ILE H  50
MET H 106
THR H 104
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6yor IGG H CHAIN
(Homo
sapiens)		3 / 3
VAL B 108
LEU B   4
GLY B  24
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6yor IGG H CHAIN
(Homo
sapiens)		5 / 12
PHE H  29
ALA H  97
ILE H  50
MET H 106
THR H 104
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 5
ALA B 172
LEU B 174
GLY B 178
THR C 135
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6yor IGG H CHAIN
(Homo
sapiens)		5 / 12
PHE B  29
ALA B  97
ILE B  50
MET B 106
THR B 104
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 5
ALA H 172
LEU H 174
GLY H 178
THR L 135
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 5
ALA E 475
LEU E 455
GLY B  15
THR B  91
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
VAL A 247
LEU A 250
GLY A 251
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.77A
None
PK8  A 401 ( 3.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
MET A  17
PHE A 150
VAL A 157
VAL A 114
GLU A  14
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
VAL A  42
LEU A  27
GLY A 146
1.56A
None
PK8  A 401 ( 3.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
ASN A 119
ALA A 116
LEU A  30
GLY A  29
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL D 165
LEU D 169
GLY E   8
0.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL E 165
LEU E 169
GLY D   8
0.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL D  24
LEU D  53
GLY D  51
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ALA E 129
TYR E  42
GLU E 104
VAL E 142
ILE E 106
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL A  41
LEU A  75
GLY A  79
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL B  41
LEU B  75
GLY B  79
1.28A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
ASN C  37
ALA C 129
LEU C 109
GLY C  97
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL E  41
LEU E  75
GLY E  79
1.27A
None
EPE  E 203 (-3.6A)
EPE  E 203 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL C  41
LEU C  75
GLY C  79
1.26A
None
EPE  C 202 (-3.4A)
EPE  C 202 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
ASN E  37
ALA E 129
LEU E 109
GLY E  97
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
ASN D  37
ALA D 129
LEU D 109
GLY D  97
1.37A
None
EDO  D 205 (-4.5A)
EDO  D 204 ( 4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL D  41
LEU D  75
GLY D  79
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL E 165
LEU E  10
GLY D   8
0.99A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
ASN B  37
ALA B 129
LEU B 109
GLY B  97
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL D 165
LEU D  10
GLY E   8
1.05A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
ASN A  37
ALA A 129
LEU A 109
GLY A  97
1.36A
None
None
None
EDO  A 202 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL E 165
LEU E 169
GLY D   8
0.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL A  24
LEU A  53
GLY A  51
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL D  24
LEU D  53
GLY D  51
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL A  41
LEU A  75
GLY A  79
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL B  41
LEU B  75
GLY B  79
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL E 165
LEU E  10
GLY D   8
1.00A
None
EDO  E 203 ( 4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL D 165
LEU D 169
GLY E   8
0.63A
None
None
EDO  E 203 (-4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
VAL E 151
ALA E 124
ALA E 112
THR E  13
ILE E  18
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL C  41
LEU C  75
GLY C  79
1.28A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
VAL E  34
ALA E  89
VAL E 151
TYR E  17
GLU E 120
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL E  41
LEU E  75
GLY E  79
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL C  24
LEU C  53
GLY C  51
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL D 165
LEU D  10
GLY E   8
1.03A
None
None
EDO  E 203 (-4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL D  41
LEU D  75
GLY D  79
1.30A
None
EDO  D 202 (-4.6A)
EDO  D 203 (-3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
VAL B  34
ALA B  89
VAL B 151
TYR B  17
GLU B 120
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL A  41
LEU A  75
GLY A  79
1.28A
None
None
EDO  A 204 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL C  24
LEU C  53
GLY C  51
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
ASN B  37
ALA B 129
LEU B 109
GLY B  97
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL C  41
LEU C  75
GLY C  79
1.28A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
ASN A  37
ALA A 129
LEU A 109
GLY A  97
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
VAL A  34
ALA A  89
VAL A 151
TYR A  17
GLU A 120
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
ASN C  37
ALA C 129
LEU C 109
GLY C  97
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
VAL B  41
LEU B  75
GLY B  79
1.27A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		7bqy MAIN PROTEASE
(SARS-CoV-2)		3 / 3
VAL A  42
LEU A  27
GLY A 146
1.56A
None
PJE  C   5 (-4.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7bqy MAIN PROTEASE
(SARS-CoV-2)		5 / 12
THR A  98
VAL A  18
ALA A  70
VAL A 148
VAL A  77
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		7bqy MAIN PROTEASE
(SARS-CoV-2)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.79A
None
PJE  C   5 (-4.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7bqy MAIN PROTEASE
(SARS-CoV-2)		5 / 12
MET A  17
PHE A 150
VAL A 157
VAL A 114
GLU A  14
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		7bqy MAIN PROTEASE
(SARS-CoV-2)		3 / 3
VAL A 247
LEU A 250
GLY A 251
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		7btf NSP12
NSP8
(SARS-CoV-2)		4 / 5
ASN B 100
ALA A 379
LEU A 401
GLY A 385
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		7btf NSP12
(SARS-CoV-2)		5 / 12
VAL A 693
ALA A 690
ALA A 639
THR A 586
ILE A 589
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7btf NSP12
(SARS-CoV-2)		5 / 12
PHE A 340
VAL A 342
ALA A 379
VAL A 338
THR A 344
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		7btf NSP7
NSP8
(SARS-CoV-2)		5 / 12
THR C   9
PHE C  49
VAL C  53
ALA C  48
ILE D 107
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7btf NSP12
(SARS-CoV-2)		5 / 12
THR A 801
PHE A 753
VAL A 776
MET A 756
THR A 586
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		7btf NSP12
(SARS-CoV-2)		4 / 5
ALA A 690
LEU A 663
GLY A 679
THR A 556
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		7btf NSP12
(SARS-CoV-2)		4 / 5
ASN A 507
ALA A 558
LEU A 544
THR A 402
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		7btf NSP12
NSP8
(SARS-CoV-2)		5 / 12
VAL B 130
ALA B 188
ALA A 400
THR B 137
THR B 141
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		7btf NSP12
NSP8
(SARS-CoV-2)		3 / 3
VAL B  83
LEU A 514
GLY A 510
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		7btf NSP12
(SARS-CoV-2)		3 / 3
VAL A 763
LEU A 614
GLY A 808
1.10A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7btf NSP12
(SARS-CoV-2)		5 / 12
PHE A 317
VAL A 315
ALA A 311
ILE A 466
MET A 629
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		7btf NSP12
(SARS-CoV-2)		5 / 12
MET A 755
VAL A 693
ALA A 699
THR A 686
ILE A 579
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7btf NSP12
(SARS-CoV-2)		5 / 12
PHE A 753
VAL A 776
VAL A 587
MET A 756
THR A 586
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		7btf NSP12
(SARS-CoV-2)		5 / 12
PHE A 753
VAL A 776
ALA A 706
ALA A 699
THR A 769
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		7btf NSP12
(SARS-CoV-2)		4 / 5
ASN A 790
ALA A 634
LEU A 663
GLY A 679
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7btf NSP12
(SARS-CoV-2)		5 / 12
THR A 567
VAL A 535
ALA A 660
VAL A 373
VAL A 299
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		7btf NSP12
NSP8
(SARS-CoV-2)		4 / 5
ASN A 507
ALA B  86
LEU B  91
THR A 402
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		5 / 12
THR A  98
VAL A  18
ALA A  70
VAL A 148
VAL A  77
1.74A
None
DMS  A 403 ( 4.9A)
DMS  A 403 ( 4.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		3 / 3
VAL A 247
LEU A 250
GLY A 251
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		3 / 3
VAL A  20
LEU A  27
GLY A 146
0.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 5
ASN A 119
ALA A 116
LEU A  30
GLY A  29
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		3 / 3
VAL A  42
LEU A  27
GLY A 146
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		7bv1 NSP12
NSP8
(SARS-CoV-2)		3 / 3
VAL B  83
LEU A 514
GLY A 510
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
PHE A 745
ALA A 777
VAL A 475
TYR A 746
THR A 710
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
PHE A 753
VAL A 776
ALA A 706
ALA A 699
THR A 769
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
PHE A 753
VAL A 776
VAL A 587
MET A 756
THR A 586
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
VAL A 763
LEU A 614
GLY A 808
1.22A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
MET A 755
VAL A 693
ALA A 699
THR A 686
ILE A 579
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
THR A 801
PHE A 753
VAL A 776
MET A 756
THR A 586
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		7bv1 NSP12
(SARS-CoV-2)		4 / 5
ALA A 690
LEU A 663
GLY A 679
THR A 556
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
PHE A 340
VAL A 342
ALA A 379
VAL A 338
THR A 344
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		7bv1 NSP12
NSP8
(SARS-CoV-2)		4 / 5
ASN A 507
ALA B  86
LEU B  91
THR A 402
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		7bv1 NSP12
NSP8
(SARS-CoV-2)		4 / 5
ASN B 118
ALA A 400
LEU B 128
THR A 394
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
PHE A 317
VAL A 315
ALA A 311
ILE A 466
MET A 629
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
VAL A 693
ALA A 690
ALA A 639
THR A 586
ILE A 589
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		7bv1 NSP12
(SARS-CoV-2)		4 / 5
ASN A 496
ALA A 688
GLY A 683
THR A 567
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
PHE A 480
ALA A 699
VAL A 637
VAL A 605
MET A 755
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
THR A 567
VAL A 535
ALA A 660
VAL A 373
VAL A 299
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		7bv1 NSP12
(SARS-CoV-2)		4 / 5
ASN A 507
ALA A 558
LEU A 544
THR A 402
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		7bv1 NSP12
NSP8
(SARS-CoV-2)		5 / 12
VAL B 130
ALA B 188
ALA A 400
THR B 137
THR B 141
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		7bv1 NSP7
NSP8
(SARS-CoV-2)		5 / 12
THR C   9
PHE C  49
VAL C  53
ALA C  48
ILE D 107
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		7bv2 NSP12
(SARS-CoV-2)		4 / 5
ASN A 790
ALA A 634
LEU A 663
GLY A 679
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
THR A 567
VAL A 535
ALA A 660
VAL A 373
VAL A 299
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		7bv2 NSP12
NSP8
(SARS-CoV-2)		4 / 5
ASN A 507
ALA B  86
LEU B  91
THR A 402
1.42A
 U  T   8 ( 3.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
THR A 801
PHE A 753
VAL A 776
MET A 756
THR A 586
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
PHE A 480
ALA A 699
VAL A 637
VAL A 605
MET A 755
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
PHE A 317
VAL A 315
ALA A 311
ILE A 466
MET A 629
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
PHE A 753
VAL A 776
VAL A 587
MET A 756
THR A 586
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
PHE A 745
ALA A 777
VAL A 475
TYR A 746
THR A 710
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		7bv2 NSP12
(SARS-CoV-2)		4 / 5
ALA A 690
LEU A 663
GLY A 679
THR A 556
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
VAL A 693
ALA A 690
ALA A 639
THR A 586
ILE A 589
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_0
(CYTOCHROME P450 2R1)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
ALA A 199
VAL A 234
TYR A 237
ILE A  86
THR A 225
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		7bv2 NSP12
NSP8
(SARS-CoV-2)		4 / 5
ASN B 118
ALA A 400
LEU B 128
THR A 394
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
VAL A 763
LEU A 614
GLY A 808
1.23A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		7bv2 NSP12
NSP8
(SARS-CoV-2)		4 / 5
ASN B 100
ALA A 379
LEU A 401
GLY A 385
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
MET A 755
VAL A 693
ALA A 699
THR A 686
ILE A 579
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_1
(CYTOCHROME P450 2R1)		7bv2 NSP12
NSP8
(SARS-CoV-2)		3 / 3
VAL B  83
LEU A 514
GLY A 510
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_B_V2HB602_0
(CYTOCHROME P450 2R1)		7bv2 NSP12
NSP8
(SARS-CoV-2)		5 / 12
VAL B 130
ALA B 188
ALA A 400
THR B 137
THR B 141
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DL9_A_V2HA602_1
(CYTOCHROME P450 2R1)		7bv2 NSP12
(SARS-CoV-2)		4 / 5
ASN A 507
ALA A 558
LEU A 544
THR A 402
1.36A
 U  T   8 ( 3.5A)
None
None
None